Michael Okunewitch
Stock Analyst at Maxim Group
(1.82)
# 3,197
Out of 4,883 analysts
26
Total ratings
25%
Success rate
-0.04%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $4.17 | +739.33% | 2 | May 29, 2025 | |
| CTOR Citius Oncology | Downgrades: Hold | n/a | $4.71 | - | 2 | May 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Maintains: Buy | $6 → $3 | $1.65 | +82.37% | 2 | May 15, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $3.84 | +212.50% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.15 | +508.70% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.40 | +900.00% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.95 | +215.66% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.97 | +312.37% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.61 | +1,883.47% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.29 | +365.12% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.87 | +1,272.21% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.25 | +1,820.00% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.81 | +540.57% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $2.88 | +70,212.50% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $19.51 | +28.14% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.52 | +294.74% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.75 | +809.09% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.11 | +4,650.59% | 1 | Nov 30, 2021 |
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $4.17
Upside: +739.33%
Citius Oncology
May 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $4.71
Upside: -
Anebulo Pharmaceuticals
May 15, 2025
Maintains: Buy
Price Target: $6 → $3
Current: $1.65
Upside: +82.37%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $3.84
Upside: +212.50%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.15
Upside: +508.70%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.40
Upside: +900.00%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.95
Upside: +215.66%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.97
Upside: +312.37%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.61
Upside: +1,883.47%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.29
Upside: +365.12%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.87
Upside: +1,272.21%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.25
Upside: +1,820.00%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.81
Upside: +540.57%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $2.88
Upside: +70,212.50%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $19.51
Upside: +28.14%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.52
Upside: +294.74%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $2.75
Upside: +809.09%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $2.11
Upside: +4,650.59%